
Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Dr. Florez and Dr. Sabari delve into areas of progress, unmet needs, and future research in NSCLC, encompassing novel biomarkers and targeted therapies such as CEACAM5.

Important findings from the CARMEN-LC05 study evaluating tusa in combination with pembrolizumab and chemotherapy in NSCLC are discussed, highlighting their implications for clinical practice.

An overview of the CARMEN-LC03 and CARMEN-LC04 trials investigating tusa in different treatment settings for NSCLC and their impact on treatment approaches is provided.

The transformative potential of antibody drug conjugates in NSCLC treatment is discussed, encompassing their design, bystander effect, biomarkers, and impact on the treatment landscape.

Dr. Florez and Dr. Sabari discuss standards of care for different patient populations in NSCLC.

Experts share their approach to CEACAM5 testing, including the testing procedure, patient selection criteria, and timing of testing.

The role of CEACAM5, its expression in NSCLC, and its potential as a therapeutic target are thoroughly examined, including its impact on tumorigenesis and prognosis in NSCLC patients.

The discussion centered around emergent biomarkers and targeted therapies in NSCLC, exploring targets like CEACAM5, TROP2, HER3, cMET, and the potential role of antibody drug conjugates in refractory disease.

A comprehensive overview of the current landscape of non-small cell lung cancer (NSCLC), highlighting the impact of biomarkers on treatment selection.

Published: August 1st 2023 | Updated:

Published: July 18th 2023 | Updated:

Published: July 18th 2023 | Updated:

Published: August 8th 2023 | Updated:

Published: July 25th 2023 | Updated:

Published: August 15th 2023 | Updated: